1 – Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and Cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer. Results of a large randomised multinational multicentre phase III study. J Clin Oncol 2000;18(17):3068-77.
2 – De Santis M, Bellmunt J, Mead G, et al. Randomised phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy. EORTC study 30986. J Clin Oncol 2012;30:191.
3 – Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomised trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin plus cisplatin in patient with bladder cancer. J Clin Oncol 2005;23(21):4602.
4 – Bellmunt J, de Wit R, Vaughan DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015.
5 – Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748.
6 – Balar AV, Galsky MD, Rosenborg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (IMVIGOR-210): a single-arm, multicentre, phase II trial. Lancet Oncol 2017;389(10064):67.
7 – Balar AV, Castellano D, O’Donnell P, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm phase-2 study. Lancet Oncol 2017;18(11):1483
8 – Petrylak D, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet Oncol 2017;390(10109):2266.
9 – Geldart T, Chester J, Casbard, et al. SUCCINCT: an open-label, single arm, non-randomised phase II trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. Eur Urol 2015;67(4):599-602.
10 – Powles T, Huddart RA, Elliott T, et al. Phase III, double-blinded, randomised trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patient with human epidermal growth factor receptor 1/2 positive metastatic bladder cancer. J Clin Oncol 2017;35(1):48-55. Epub 2016 Oct 28.
11 – Kopparapu PK, Boorjian SA, Robinson BD et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Research 2013;33(6):2381-90
12 – Cheng HL, Trink B, Tzai TS et al. Over-expression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002;20(6):1544-50.
13 – Miyata Y, Sagara Y, Kanda S et al. Phosphorylated hepatocyte growth factor receptor /c-MET is associated with tumour growth and prognosis in patients with bladder cancer: correlation with matrix metalloprotease-2 and -7 and E-cadherin. Human Pathology 2009;40(4):496-504.
14 – Elisei R, Schlumberger MJ, Mueller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29):3639.
15 – Apolo AB, Parnes HL, Madan RA, et al. A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. J Clin Oncol 2013;31(15).
16 – Nickerson ML, Dancik GM, IM KM, et al. Concurrent alterations in TERT, KDM6A and the BRCA pathway in bladder cancer. Clin Cancer Res 2014;20(18):4935-48.
17 – Yap KL, Kiyotani K, Tamura K, et al. Whole genome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res 2014;20(24):6605-17.
18 – Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-21.
19 – Ledermann J, Harter P, Courley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92.
20 – Wu JT, Han BM, Yo SQ, et al. Androgen receptor is a potential therapeutic target for bladder cancer. Urology 2010;75(4):820-7.
21 – Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the bladder. BJU International 2012;109(11):1716-26.
22 – Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33.